A computational model for genetic and epigenetic signals in colon cancer
Tóm tắt
Cancer, a class of diseases, characterized by abnormal cell growth, has one of the highest overall death rates world-wide. Its development has been linked to aberrant genetic and epigenetic events, affecting the regulation of key genes that control cellular mechanisms. However, a major issue in cancer research is the lack of precise information on tumour pathways; therefore, the delineation of these and of the processes underlying disease proliferation is an important area of investigation. A computational approach to modelling malignant system events can help to improve understanding likely “triggers”, i.e. initiating abnormal micro-molecular signals that occur during cancer development. Here, we introduce a network-based model for genetic and epigenetic events observed at different stages of colon cancer, with a focus on the gene relationships and tumour pathways. Additionally, we describe a case study on tumour progression recorded for two gene networks on colon cancer, carcinoma in situ. Our results to date showed that tumour progression rate is higher for a small, closely-associated network of genes than for a larger, less-connected set; thus, disease development depends on assessment of network properties. The current work aims to provide improved insight on the way in which aberrant modifications characterize cancer initiation and progression. The framework dynamics are described in terms of interdependencies between three main layers: genetic and epigenetic events, gene relationships and cancer stage levels.
Tài liệu tham khảo
Ahuja, N., Li, Q., Mohan, A.L., Baylin, S.B., Issa, J.P.J. 1998. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res 58, 5489–5494.
Allis, C.D., Jenuwein, T., Reinberg, D., Caparros, M.L. 2007. Epigenetics. Cold Spring Harbor Laboratory Press, New York.
Barat, A., Ruskin, H.J. 2010. A manually curated novel knowledge management system for genetic. Open Colorectal Canc J 3, 36–46.
Bast, R.C., Hennessy, B., Mills, G.B. 2009. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9, 415–428.
Bjornsson, H.T., Fallin, D.M., Feinberg, A.P. 2004. An integrated epigenetic and genetic approach to common human disease. Trends Genet 20, 350–358.
Bock, C., Lengauer, T. 2008. Computational epigenetics. Bioinformatics 24, 1–10.
Brenner, H., Hoffmeister, M., Arndt, V., Haug, U. 2007. Gender differences in colorectal cancer: Implications for age at initiation of screening. Br J Cancer 96, 828–831.
Burnside, E.S., Rubin, D.L., Fine, J.P., Shachter, R.D., Sisney, G.A, Leung, W.K. 2006. Bayesian network to predict breast cancer risk of mammographic microcalcifications and reduce number of benign biopsy results: Initial experience. Radiology 240, 666–673.
Carrillo-Infante, C., Abbadessa, G., Bagella, L., Giordano, A. 2007. Viral infections as a cause of cancer. Int J Oncol 30, 1521–1528.
Cedar, H., Bergman, Y. 2009. Linking DNA methylation and histone modification: Patterns and paradigms. Nat Rev Genet 10, 295–304.
Coleman, W.B., Rivenbark, A.G. 2006. Quantitative DNA methylation analysis: The promise of highthroughput epigenomic diagnostic testing in human neoplastic disease. J Mol Diagn 8, 152–156.
Dworkin, A.M., Huang, T.H.M., Toland, A.E. 2009. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 19, 165–171.
Egger, G., Liang, G., Aparicio, A., Jones, P.A. 2004. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463.
Fraga, M.F., Agrelo, R., Esteller, M. 2007. Cross-talk between aging and cancer. Ann NY Acad Sci 1100, 60–74.
Fraga, M.F., Esteller, M. 2007. Epigenetics and aging: The targets and the marks. Trends Genet 23, 413–418.
Frank, S.A. 2007. Dynamics of Cancer: Incidence, Inheritance, and Evolution. Princeton University Press, Oxfordshire, New Jersey.
Heckerman, D. 2008. A tutorial on learning with Bayesian networks. In: Holmes, D.E. and Lakhmi, C.J. (Eds.) Innovations in Bayesian Networks. Springer, Berlin Heidelberg, 33–82.
Hemminki, K., Zhang, H., Czene, K. 2003. Familial and attributable risks in cutaneous melanoma: Effects of proband and age. J Invest Dermatol 120, 217–223.
Herman, J.G., Baylin, S.B. 2003. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349, 2042–2054.
Hou, L., Zhang, X., Wang, D., Baccarelli, A. 2012. Environmental chemical exposures and human epigenetics. Int J Epidemiol 41, 79–105.
Jansen, R., Yu, H., Greenbaum, D., Kluger, Y., Krogan, N.J., Chung, S., Emili, A., Snyder, M., Greenblatt, J.F., Gerstein, M. 2003. A Bayesian networks approach for predicting protein-protein interactions from genomic data. Science 302, 449–453.
Jelinic, P., Shaw, P. 2007. Loss of imprinting and cancer. J Pathol 211, 261–268.
Jones, P.A., Baylin, S.B. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415–428.
Karpf, A.R., Jones, D.A. 2002. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21, 5496–5503.
Knudson, A.G. 2001. Two genetic hits (more or less) to cancer. Nat Rev Cancer 1, 157–162.
Laird, P.W. 2003. The power and the promise of DNA methylation markers. Nat Rev Cancer 3, 253–266.
Lim, S.J., Tan, T.W., Tong, J.C. 2010. Computational Epigenetics: The new scientific paradigm. Bioinformation 4, 331–337.
Oakeley, E.J. 1999. DNA methylation analysis: A review of current methodologies. Pharmacol Ther 84, 389–400.
Ogino, S., Kawasaki, T., Brahmandam, M., Cantor, M., Kirkner, G.J., Spiegelman, D., Makrigiorgos, G.M., Weisenberger, D.J., Laird, P.W., Loda, M. 2006. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8, 209–217.
Ongenaert, M., Van Neste, L., De Meyer, T., Menschaert, G., Bekaert, S., Van Criekinge, W. 2008. PubMeth: A cancer methylation database combining text-mining and expert annotation. Nucl Acid Res 36, D842–D846.
Perrin, D., Ruskin, H.J., Niwa, T. 2010. Cell typedependent, infection-induced, aberrant DNA methylation in gastric cancer. J Theor Biol 264, 570–577.
Raghavan, K., Ruskin, H.J. 2011. Computational epigenetic micromodel-framework for parallel implementation and information flow. In: Proceedings of The Eighth International Conference on Complex Systems, Boston, USA, 340–353.
Risch, A., Plass, C. 2008. Lung cancer epigenetics and genetics. Int J Cancer 123, 1–7.
Safran, M., Dalah, I., Alexander, J., Rosen, N., Stein, T.I., Shmoish, M., Nativ, N., Bahir, I., Doniger, T., Krug, H., Sirota-Madi, A., Olender, T., Golan, Y., Stelzer, G., Harel, A., Lancet, D. 2010. GeneCards Version 3: The human gene integrator. Database (Oxford) 2010, DOI: 10.1093/database/baq020.
Samaras, V., Rafailidis, P.I., Mourtzoukou, E.G., Peppas, G., Falagas, M.E. 2010. Chronic bacterial and parasitic infections and cancer: A review. J Infect Dev Ctries 4, 267–281.
Steele, R.J.C., Thompson, A.M., Hall, P.A., Lane, D.P. 1998. The p53 tumour suppressor gene. Br J Surg 85, 1460–1467.
Vogelstein, B., Kinzler, K.W. 2004. Cancer genes and the pathways they control. Nat Med 10, 789–799.